Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 18Active not recruiting 16Recruiting 15Not yet recruiting 3Unknown 2Terminated 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasms 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Interventional × capivasertib × Clear all
NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

OHSU Knight Cancer Institute

Phase 2 Terminated
24 enrolled 16 charts
Breast

Triple Negative Breast Neoplasms

NCT02576444 2022-12-28

OLAPCO

Yale University

Phase 2 Terminated
67 enrolled 10 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡